The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?

Affiliations

¹ Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.

^# Contributed equally.

Comment

Feihu Xie et al. Hepatobiliary Surg Nutr. 2018 Jun.

. 2018 Jun;7(3):221-224.

doi: 10.21037/hbsn.2018.06.06.

¹ Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.

^# Contributed equally.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Kudo M, et al. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. Lancet. 2018. PMID: 29433850 Clinical Trial.

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14. 10.1016/S0140-6736(18)30010-2 - DOI - PubMed
1. Coskun A, Yavasoglu I, Yasa MH, et al. Cetirizine-induced hepatotoxicity: case series and review of the literature. Gastroenterol Rep (Oxf) 2016. [Epub ahead of print]. 10.1093/gastro/gow025 - DOI - PMC - PubMed
1. Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis. Cancer Biol Med. 2018; 15:124-36. 10.20892/j.issn.2095-3941.2018.0018 - DOI - PMC - PubMed
1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. 10.1016/S0140-6736(18)30207-1 - DOI - PubMed
1. Elwir S, Hal H, Veith J, et al. Radiographical findings in patients with liver cirrhosis and hepatic encephalopathy. Gastroenterol Rep (Oxf) 2016;4:221-5. 10.1093/gastro/gov049 - DOI - PMC - PubMed